Loading...
•
Sep 30, 2021
ORIC Pharmaceuticals Q3 2021 Earnings Report
ORIC Pharmaceuticals reported financial results for Q3 2021 and provided an operational update.
Key Takeaways
ORIC Pharmaceuticals reported its Q3 2021 financial results, highlighting the advancement of its pipeline, including initial clinical data from the ORIC-101 Phase 1b trial and preclinical data on ORIC-114. The company's cash and investments of $296.5 million are expected to fund operations into 2024.
Initial clinical data from Phase 1b trial of ORIC-101 in combination with enzalutamide was presented at AACR-NCI-EORTC.
Preclinical data on ORIC-114 was presented at AACR-NCI-EORTC.
An update on the oral CD73 inhibitor program will be presented at the American Society of Hematology (ASH) Annual Meeting.
Phase 1 trial initiation of single agent ORIC-533 in patients with multiple myeloma is expected in 4Q 2021.
ORIC Pharmaceuticals
ORIC Pharmaceuticals
Forward Guidance
ORIC anticipates several milestones in the fourth quarter of 2021.
Positive Outlook
- Present update on oral CD73 inhibitor program at the ASH Annual Meeting
- Initiate single agent Phase 1 trial in patients with multiple myeloma (ORIC-533)
- File IND for ORIC-944
- CTA filing submitted for ORIC-114
- IND filing for ORIC-944 expected in 4Q 2021